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Interferon-c Decreases Ceramides with Long-Chain
Fatty Acids: Possible Involvement in Atopic Dermatitis
and Psoriasis
Chisato Tawada1, Hiroyuki Kanoh1, Mitsuhiro Nakamura2, Yoko Mizutani1, Tomomi Fujisawa1,
Yoshiko Banno1 and Mariko Seishima1
Ceramide (CER) with long-chain fatty acids (FAs) in the human stratum corneum (SC) is important for the skin
barrier functions. Changes in the CER profile have been associated with abnormal permeability of dermatoses
such as atopic dermatitis (AD) and psoriasis. In addition, interferon-g (IFN-g) has been known to be abundant in
both AD and psoriatic skin lesions. In this study, we aimed to identify the mechanism underlying the alteration of
FA chain length of CERs in these diseases. Mass spectrometry analysis of CERs in the SC showed that the
proportion of CERs with long-chain FAs was significantly lower in AD and psoriasis patients than in healthy
controls, and this reduction was more pronounced in psoriasis than in AD. Using cultured human keratinocytes
and epidermal sheets, we found that only IFN-g among various cytokines decreased the mRNA expression of
elongase of long-chain fatty acids (ELOVL) and ceramide synthase (CerS), enzymes involved in FA chain
elongation. Furthermore, quantitative analysis showed that IFN-g decreased the levels of CERs with long-chain
FAs. These results suggest that IFN-g decreases CERs with long-chain FAs through the downregulation of ELOVL
and CerS and that this mechanism may be involved in the CER profile alteration observed in psoriasis and AD.
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INTRODUCTION
In the human stratum corneum (SC), ceramides (CERs) are
responsible for maintaining a hydrophobic environment, and
they have an important role in the development and main-
tenance of the water permeability barrier of the skin (Choi and
Maibach, 2005; Feingold, 2007). Atopic dermatitis (AD) is a
chronic relapsing inflammatory skin disease characterized by
abnormality in SC permeability. The changes in the CER
profile of AD patients have been explored extensively, and the
characteristic abnormality in SC permeability has been
associated with decreased CER levels (Imokawa et al., 1991;
Di Nardo et al., 1998; Choi and Maibach, 2005). Psoriasis is
an immune-mediated inflammatory and proliferative disorder
of the skin that causes hyperkeratotic skin lesions. Changes in
the CER profile of psoriasis patients have also been associated
with impaired barrier functions (Motta et al., 1993, 1994);
however, the fatty acid (FA) profile of CERs in psoriasis is not
well studied.
A recent study revealed that there are 342 CER species,
which can be divided into 11 classes (Masukawa et al., 2008).
Further, improved SC barrier function strongly correlates with
the average FA chain length of CERs (Ishikawa et al., 2010; Joo
et al., 2010; Janu˚sˇova´ et al., 2011). Thus, both the amount
and the FA profiles of CERs are critical for SC barrier function.
Therefore, in this study, we analyzed the CER profiles of
SC in AD and psoriasis patients by using matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF-MS). To elucidate the mechanisms underlying
the alteration of FA length in CERs, we focused on two
enzymes: elongase of long-chain fatty acids (ELOVL) and
CER synthase (CerS), which are involved in the elongation of
FAs of CERs (Mizutani et al., 2009; Guillou et al., 2010).
Both AD and psoriasis are associated with immuno-
logical abnormalities, including dysregulation of T helper
(Th) type 1 and type 2 (Th1/Th2) and Th1/Th17 cells,
respectively (Del Prete, 1992; Nestle et al., 2009). In
addition, interferon-g (IFN-g), a Th1 cytokine, has been
shown to be highly expressed in the skin lesions of both
diseases (Barker et al., 1991; Grewe et al., 1994, 1998; Szabo
et al., 1998; Lowes et al., 2008; Bieber, 2010). Therefore, we
examined the effects of various cytokines on the mRNA
expression levels of ELOVL and CerS using normal human
epidermal keratinocytes (NHEKs) and reconstructed three-
dimensional epidermis.
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RESULTS
Decreased molecular size of CERs in tape-stripped SC of AD and
psoriasis patients by MALDI-TOF-MS analysis
Sixty-three peaks above background noise, which consisted of
8 CER classes and covered 297 CER species out of 342
species, were detected between m/z values of 608 and 820
(Supplementary Figure S1 online). Three classes of omega-
hydroxy CERs, i.e, CER[EOS], CER[EOH], and CER[EOP] were
not detected. Distributions of total carbon numbers of CERs in
AD and psoriasis patients were analyzed. The proportion of
CER[NH] with total carbon number between 40 and 43 (C40–
C43 CER[NH]) was higher, whereas that of C47–C50 CER[NH]
was lower in both AD and psoriasis patients than in healthy
controls (Figure 1a and c). The proportion of C44–C46
CER[NH] decreased only in psoriasis (Figure 1b). Similar
changes in CER[ADS]/[NP] and CER[AP] levels were observed
in psoriasis but not in AD; the proportion of C38–C43
CER[ADS]/[NP] and C38–C42 CER[AP] increased, whereas that
of C49–C52 CER[ADS]/[NP] and C45–C48 CER[AP] decreased.
Significant difference in the proportion of C44–C48 CER[ADS]/
[NP] was also observed between psoriasis patients and
controls (Figure 1d–i). No obvious difference was observed
in the proportion profiles of CER[AH]/[NS] and CER[NDS]/
[AS] among psoriasis, AD, and control (data not shown).
IFN-c reduced mRNA levels of ELOVL and CerS in NHEKs
The effects of cytokines involved in the pathophysiology
of these diseases on ELOVL and CerS mRNA expression
were examined in cultured NHEKs. The NHEKs expressed
ELOVL1, ELOVL4, ELOVL5, ELOVL6, ELOVL7, CerS2,
CerS3, CerS5, and CerS6, whereas the expression levels of
ELOVL2, ELOVL3, CerS1, and CerS4 were minimal
(Supplementary Figure S2 online). When NHEKs were
stimulated with interleukin (IL)-1, IL-4, IL-5, IL-8, IL-17, IL-
18, IFN-g, TNF-a (tumor necrosis factor-a), or GM-CSF
(granulocyte macrophage colony-stimulating factor), only
IFN-g reduced the expression levels of ELOVL4, ELOVL5,
CerS3, and CerS6 by 84, 39, 52, and 62%, respectively
(Figure 2). Expression levels of other isozymes were not
changed by IFN-g (data not shown). The expression levels of
ELOVL4 and CerS3 were reduced by IFN-g in a time- and
dose-dependent manner, and maximum suppression was
achieved at 14 hours with 50 ng ml1 (Supplementary Figure
S3 online). IFN-a, IFN-b, IL-6, IL-22, IL-23, and thymic
stromal lymphopoietin had no effect on the mRNA expres-
sion of ELOVL4 and CerS3 (data not shown). Cytokines in
combination, i.e, IL-4 plus IL-5 and IL-22 plus IL-23, also
had no effect on the expression levels of ELOVL4 and CerS3
(data not shown).
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Figure 1. Ceramide (CER) profiles in the stratum corneum (SC) of atopic dermatitis (AD) and psoriasis patients and healthy controls. CER was collected from
the SC in the lesional skin of AD patients (n¼ 15) and psoriasis patients (n¼ 15) and from the normal skin of healthy individuals (n¼ 22). CER species
of eight classes were identified by MALDI-TOF-MS (matrix-assisted laser desorption/ionization time-of-flight mass spectrometry) and were sorted into five
groups. Each peak was measured, and the relative percentage to total intensity in each group was calculated. Three groups (CER[NH] (a–c), CER[ADS]/[NP]
(d–f), and CER[AP] (g–i)) with significant differences are shown. For pair-wise comparisons, Student’s t-test was used (**Po0.01).
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IFN-c reduced mRNA levels of ELOVL and CerS in reconstructed
three-dimensional epidermis
In reconstructed three-dimensional epidermis, IFN-g
(100 ng ml1) reduced the mRNA levels of ELOVL1, ELOVL6,
and ELOVL7 by 57.3, 52.0, and 46.0%, respectively
(Figure 3a) and those of CerS3, CerS4, and CerS6 by 66.2,
30.9, and 22.8%, respectively (Figure 3b). On the other hand,
the mRNA levels of CerS2 and CerS5 were increased by IFN-g.
The mRNA level of ELOVL4 was reduced by IFN-g at
200 ng ml 1 but not at 100 ng ml1 (data not shown).
IFN-c reduced the amount of CER[NS] with long-chain FA in
reconstructed three-dimensional epidermis during SC formation
The amount of CER[NS] was analyzed by ion trap/time-of-
flight mass spectrometry coupled with high-performance
liquid chromatography (LCMS-IT-TOF). Three-dimensional
epidermal sheets on day 7, which possessed minimal SC,
were cultured for an additional 7 days in the presence of
IFN-g. By day 14, the three-dimensional epidermal sheets
formed multi-layered SC. The amounts of CER[NS] with long-
chain FAs, from CER[N(20)S(18)] to CER[N(26)S(18)], were
reduced in a dose-dependent manner (Figure 4). Under the
same culturing conditions, mRNA levels of ELOVL1 and CerS3
were reduced by IFN-g in a dose-dependent manner, and this
reduction corresponded to the decrease in CER[NS] with long-
chain FAs (data not shown).
Signal transducer and activator of transcription (STAT)-
independent pathway of IFN-c mediated downregulation of
ELOVL and CerS
To elucidate the IFN-g signaling pathway involved in CER
metabolism, the effect of Janus kinase (JAK) inhibitor Pyridon 6
was examined in NHEKs; Pyridon 6 (1mM) treatment restored
the mRNA levels of ELOVL4 and CerS3, which were sup-
pressed by IFN-g (Figure 5a and b). Next, to examine the
downstream effectors of JAK, STAT1 was knocked down in
NHEKs using small-interfering RNA (siRNA). STAT1 mRNA
level increased by 3.7-fold in control NHEKs treated with
50 ng ml1 of IFN-g. In siRNA-treated NHEKs, the basal
level of STAT1 mRNA was 24.0% of that in control cells,
and IFN-g-stimulated level was less than the basal level in
control cells, confirming that the siRNA was functioning (data
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Figure 2. Interferon (IFN)-c reduced mRNA levels of elongase of long-chain
fatty acids (ELOVL) and ceramide synthase (CerS) in normal human epidermal
keratinocytes (NHEKs). NHEKs were stimulated with interleukin (IL)-1, IL-4,
IL-5, IL-8, tumor necrosis factor (TNF)-a, granulocyte macrophage colony-
stimulating factor (GM-CSF), and IFN-g (50ng ml1 each), IL-18
(100 ng ml1), and IL-17 (200 ng ml1) for 24 hours. Total RNA was extracted
and subjected to quantitative reverse-transcriptase–PCR for measurements of
(a) ELOVL4, (b) ELOVL5, (c) CerS3, and (d) CerS6. Data are presented as
mean±SD (**Po0.01).
0
0.04
ELOVL1 ELOVL2 ELOVL3 ELOVL4 ELOVL5 ELOVL6 ELOVL7
0.08
EL
O
VL
 m
RN
A
0.12
0.16
0.2
**
**
Control
IFN-γ
*
0
0.01
CerS1 CerS2 CerS3 CerS4 CerS5 CerS6
Ce
rS
 m
RN
A 0.02
0.03
**
**
*
*
*
Control
IFN-γ
Figure 3. Interferon (IFN)-c reduced mRNA levels of elongase of long-chain
fatty acids (ELOVL) and ceramide synthase (CerS) in reconstructed three-
dimensional epidermis. Reconstructed three-dimensional epidermis at day 7
was stimulated with IFN-g (100 ng ml 1) and incubated for an additional 7
days. Total RNA was extracted and subjected to quantitative reverse-
transcriptase–PCR for determining the levels of (a) ELOVLs and (b) CerSs.
Data are relative values to GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) mRNA and presented as mean±SD (*Po0.05, **Po0.01).
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not shown). However, suppression of ELOVL4 and CerS3
mRNA expression by IFN-g was not eliminated by the siRNA
treatment (Figure 5c and d). Further, siRNA-mediated knock-
down of STAT3 did not affect downregulation of ELOVL4
mRNA expression by IFN-g (data not shown). Therefore, we
examined inhibitors of other factors that could act in coopera-
tion with or independently of STAT1, i.e, MEK (mitogen-
activated protein kinase/extracellular signal–regulated kinase
(MAPK/ERK) kinase), JNK, p38MAPK, and PI3 kinase (phos-
phatidylinositol 30-kinase), but these inhibitors did not affect
the IFN-g-induced downregulation of ELOVL4 mRNA (data
not shown).
DISCUSSION
In this study, we first aimed to analyze the lengths of FAs in
CERs of AD and psoriasis patients, because CER abnormalities
in the SC have been reported for both diseases. Analysis by
MALDI-TOF-MS showed significant differences in the FA
composition profiles of CERs of the SC between AD and
psoriasis patients and normal controls. These differences were
detected in specific CER classes: CER[NH], CER[ADS]/[NP],
and CER[AP]. However, unexpectedly, significant differences
between AD patients and controls were found only in
CER[NH], while shortening of FA chain length in other classes
of CER has been reported (Ishikawa et al., 2010). The reason
for the discrepancy is not well understood. In contrast to AD,
significant differences were detected in the FA composition
profiles of CERs between psoriasis patients and normal
controls in a wide range of CER classes—not only in CER[NH]
but also in the CER[ADS]/[NP] and CER[AP] classes. Several
studies have investigated the relation between CERs and
barrier function in psoriasis. Decreased CER content in
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psoriatic skin lesion correlates with increased transepidermal
water loss (Motta et al., 1993, 1994). The de novo synthesis of
CER was significantly lower in lesional epidermis than in non-
lesional epidermis and had a negative correlation with the
clinical severity of psoriasis (Cho et al., 2004). Although
evidence accumulated over the past decade suggests that
psoriasis is a T-cell disease, it has been proposed that the
epidermal barrier dysfunction caused by disruption of CER
synthesis is involved in the pathogenesis of psoriasis (Wolf
et al., 2012). To our knowledge, our data provide previously
unreported evidence concerning the FA composition of CER in
psoriasis, and interestingly, these compositional changes were
more pronounced in psoriasis than in AD.
We have found that IFN-g reduced mRNA expressions of
ELOVL and CerS. We have also shown by quantitative
analysis of CER[NS] using LCMS-IT-TOF that IFN-g reduced
the amount of CER[NS] with long-chain FAs in reconstructed
three-dimensional epidermis. The FA composition differences
may be caused by change in the activities of the two enzymes.
CERs are synthesized by CerS from a sphingoid base and a
fatty acyl-CoA. Although fatty acyl-CoAs with carbon chains
up to C16 are synthesized by a FA synthase complex,
generation of longer FAs requires ELOVL (Jakobsson et al.,
2006). CerS is not involved in FA production per se; however,
6 CerS isoforms have been identified, each isoform exhibiting
preference for a different fatty acyl-CoA on the basis of FA
chain length, suggesting that the enzyme may also affect the
FA chain length of CERs (Pewzner-Jung et al., 2006; Mizutani
et al., 2009). CerS3 displays a strong affinity for acyl-CoAs
with a chain length of C28 or longer, suggesting that CerS3 has
an important role in the production of CERs with very long-
chain FAs (Rabionet et al., 2008). Of the six CerS isozymes,
CerS3 is highly expressed in the skin and is the predominantly
expressed isozyme in differentiated human keratinocytes
followed by CerS4 (Mizutani et al., 2008). Further, CerS3 defici-
ency in mice results in complete loss of CER with very long-
chain FAs, causing lethal skin barrier impairment (Jennemann
et al., 2012). Our results showed that IFN-g strongly reduced
expression of CerS3 mRNA not only in NHEKs but also in
reconstructed three-dimensional epidermis. These results suggest
that CerS3 may be a key enzyme involved in IFN-g-induced
shortening of the FA chains of CERs in the human skin.
Seven elongases (ELOVL1–7) have been identified in mam-
mals, and each isoform has been shown to exhibit a
characteristic substrate specificity. ELOVL1 is important for
elongation of saturated long-chain FAs from C20 to C26
(Guillou et al., 2010; Ohno et al., 2010). Knockdown of
ELOVL1 in HeLa cells results in reduction of C24 CER and
increase in C16 and C18 CERs (Ohno et al. 2010). Further-
more, experiments using mice deficient in ELOVL1 have
shown that ELOVL1 is a key determinant of FA chain length
of CER in epidermis and is essential for permeability barrier
formation (Sassa et al., 2013). ELOVL4 is also an essential
elongase for the production of very long-chain FAs (Guillou
et al., 2010; Uchida, 2011). As in the case of ELOVL1, mice
lacking ELOVL4 are unable to produce an adequate amount of
long FAs and fail to develop a functionally competent
cutaneous permeability barrier (Cameron et al., 2007; Li
et al., 2007; Vasireddy et al., 2007). In this study, in recon-
structed three-dimensional epidermis, ELOVL1 showed the
highest gene expression among the seven isoforms, and IFN-g
significantly reduced ELOVL1 mRNA level. On the other
hand, in NHEKs, IFN-g reduced the expression of ELOVL4
and ELOVL5 but not of ELOVL1. These expression differences
may be due to the different cell types; NHEKs mimic basal
cells, whereas reconstructed three-dimensional epidermis
mimics whole epidermis, which is considered a better
physiological model than NHEKs. Therefore, ELOVL1 may
be another key enzyme involved in IFN-g-induced shortening
of the FA chains of CERs in the human skin. Taken together,
these data strongly suggest that IFN-g downregulates ELOVL1
and CerS3, which in turn reduces the levels of CERs with long-
chain FAs in the human skin.
IFN-g is one of the most potent proinflammatory cytokines
secreted by Th1 lymphocytes. Although recent advances in
research have shown that Th17 cells, rather than Th1 cells,
are the main modulators in the pathogenesis of psoriasis
(Di Cesare et al., 2009; Nestle et al., 2009), increased
number of IFN-g-producing T cells and elevated IFN-g level
have been confirmed in psoriatic lesions, indicating that the
predominant presence of IFN-g is still a characteristic of
psoriatic skin lesions (Barker et al., 1991; Szabo et al., 1998;
Lowes et al., 2008). In contrast, systemic Th2 imbalance with
increased immunoglobulin E levels and eosinophils is widely
accepted as the pathogenesis of AD (Del Prete, 1992).
However, the inflammation in the skin lesion is biphasic
with an initial Th2 phase followed by development of chronic
lesions harboring Th1 cells. Furthermore, IFN-g mRNA and
protein are highly expressed in the skin lesions in a vast
majority of AD cases (Grewe et al., 1994, 1998; Bieber, 2010).
In the present study, we did not provide any direct evidence
that IFN-g downregulates the expression of ELOVL and/or
CerS in the skin lesions of psoriasis and AD patients. However,
downregulation of ELOVL has been documented in the skin of
psoriatic patients by transcriptome analysis (Gudjonsson et al.,
2010). In the murine AD model, both downregulation of
ELOVL and decreased levels of CER with very long-chain FAs
have been reported (Park et al., 2012). Furthermore, we have
shown in the present study that change in the FA chain length
of CERs was more pronounced in psoriasis than in AD. This
may be attributable to the difference in the extent of IFN-g
infiltration in the skin lesions in the two diseases. Thus, it is
suggested that IFN-g may be a key cytokine in the production
of CERs with short chain FAs in both AD and psoriasis.
The JAK-STAT cascade is an essential signaling pathway that
mediates IFN-g-induced gene expression. However, recent
studies show that IFN-g initiates signaling cascades, including
MEK, JNK, p38MAPK, and PI3 kinase, which may act inde-
pendently of STAT1 (Ramana et al., 2001; Platanisas, 2005;
Gough et al., 2008). Our data show that IFN-g-induced mRNA
suppression of ELOVL4 and CerS3 was abolished by a JAK
inhibitor but not by knockdown of STAT1. This indicates that
the effects of IFN-g were mediated through its receptor and not
through the STAT1-dependent pathway. As all other signaling
inhibitors tested in this study had no effect, we could not decide
a specific STAT1-independent pathway in this study.
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In conclusion, our results strongly suggest that the IFN-g-
induced suppression of ELOVL1 and CerS3 decreases the
levels of CERs with long-chain FAs in the human skin. Thus,
the FA profile abnormalities in the CERs of patients with
psoriasis and AD may be attributable to the increased IFN-g
levels, which have been reported in the skin lesions of these
diseases.
MATERIALS AND METHODS
Nomenclature of CER
CER classes were expressed as the combination of FA residues and
sphingoid bases as described previously (Masukawa et al., 2008).
Namely, non-hydroxy fatty acid, a-hydroxy fatty acid, ester-linked
non-hydroxy fatty acid, o-hydroxy fatty acid, dihydrosphigosine,
sphingosine, phytosphingosine, and 6-hydroxy-sphingosine moieties
are designated as N, A, E, O, DS, S, P, and H, respectively, and, for
example, non-hydroxy dihydrosphingosine-type CER is expressed as
CER[NDS].
Subjects and sample collection from the human skin
This study was approved by the ethical committee of Gifu University
Graduate School of Medicine and performed in accordance with the
Declaration of Helsinki Principles. Written informed consent was
obtained from all volunteers and patients. Samples were collected
from 15 subjects with moderate AD (9 men and 6 women; aged 13–
72 years; mean age, 32.9±17.3 years), 15 subjects with psoriasis (12
men and 3 women; aged, 42–83 years; mean age, 63.5±14.5 years),
and 22 healthy individuals without a history of skin disorders (7 men
and 15 women; aged 1–84 years; mean 47.5±23.3 years). To obtain
SC specimens, a polyphenylene sulfide film tape (Nichiban, Tokyo,
Japan) with an area of 10 mm 60 mm was pressed on the lesional
skin of patients with AD or psoriasis or on the inner forearms of
healthy individuals and stripped; this process was repeated 10
consecutive times at the same site. The tapes were stored at
 40 1C until lipid extraction.
Lipid extraction from the SC and analysis using MALDI-TOF-MS
Lipid extraction was performed as described previously with a slight
modification (Masukawa et al., 2009). The tape was immersed in
methanol with sonication for 15 minutes. The lipid extract was dried
under a nitrogen stream, dissolved in chloroform, and applied to a
Sep-Pak Vac RC silica cartridge (Waters, Milford, MA). The CER-
containing fraction was eluted by chloroform/methanol (95:5; v/v),
dried under a nitrogen stream, and dissolved in tetrahydrofuran. The
solution was mixed with the MALDI matrix solution (1:10; v/v) and
subjected to analysis by MALDI-TOF-MS (Bruker Daltonics, Billerica,
MA) according to the manufacturer’s instruction. Mass spectra
obtained were analyzed by peak-picking, and then each peak was
identified according to the correspondence table between m/z values
and all CER species described in the previous report (Masukawa et al.,
2009). CER[ADS] and CER[NP], CER[NS] and CER[AH], and
CER[NDS] and CER[AS] share most of their m/z values with each
other, thus they were analyzed as CER[ADS] /[NP], CER[NS]/[AH], and
CER[NDS]/[AS], respectively. Intensity of each peak was expressed as
the percentage of the total intensity in each CER group. The peak at
m/z value of 663 was an artifact from the tape used for stripping
(Supplementary Figure S1 online). It should be noted that in MALDI
analysis quantitative comparisons between samples and between
values at different m/z points in the same sample are not possible;
therefore, only relative compositions of CERs with different m/z values
are available for comparison between the samples.
Cell culture and reconstructed three-dimensional epidermis
NHEKs isolated from the neonatal skin were purchased from Kurabo
(Tokyo, Japan) and cultured in Clonetics KGM-Gold medium (Lonza,
Walkersville, MD) supplemented with bovine pituitary extract,
human epidermal growth factor, recombinant human insulin, hydro-
cortisone, epinephrine, and transferrin. LabCyte EPI-MODEL (Japan
Tissue Engineering, Aichi, Japan) consisting of multilayered foreskin-
derived human keratinocytes was used as a reconstructed three-
dimensional epidermis, which was cultured in DMEM (Dulbecco’s
modified Eagle’s medium): HamF12 (1:3) supplemented with 5% fetal
bovine serum and 1.5 mM CaCl2. After IFN-g was added, incubation
was continued for the indicated period with daily replacement of the
culture medium. Whole epidermal sheet was then carefully peeled
from the membrane filter of the culture insert and subjected to
quantitative reverse-transcriptase–PCR or lipid analysis by LCMS-IT-
TOF. All cytokines tested were obtained from Wako (Osaka, Japan).
JAK inhibitor Pyridon 6 was purchased from Merck (Billerica, MA).
Lipid extraction from epidermal sheet and analysis by LCMS-IT-
TOF
The whole epidermal sheet was lysed by sonication in RIPA
(radio-immunoprecipitation assay) buffer supplemented with pro-
tease and phosphatase inhibitors, and lipids were extracted from
the cell lysates (200mg proteins) using a modified Bligh and
Dyer procedure as described previously (Nemoto et al., 2009).
C17-ceramide (Avanti Polar Lipids, Alabaster, AL), which does
not exist in the epidermis, was added before lipid extraction as
an internal standard for quantification. The lipid extract was
then analyzed by LCMS-IT-TOF (Shimadzu, Kyoto, Japan) using the
following commercially available standards: CER[N(16)S(18)],
CER[N(18)S(18)], CER[N(20)S(18)], CER[N(22)S(18)], CER[N(24)S(18)],
and CER[N(26)S(18)] (Avanti Polar Lipids, Alabaster, AL). Chromato-
graphic separations were carried out in a gradient mode using a con-
ventional ODS column (Cadenza CD-C18, 2.0 i.d. 100 mm; particle
size, 3mm; Imtakt, Kyoto, Japan). MS detection was performed with an
electrospray ionization source in positive ion mode.
Quantitative reverse-transcriptase–PCR
Total RNA was isolated from NHEKs or reconstructed three-dimen-
sional epidermis by using an RNA purification kit (NucleoSpin RNA;
Macherey-Nagel, Du¨ren, Germany), followed by reverse transcription
using the PrimeScript reverse transcriptase, oligo dT, and random
primers (all from Takara Bio, Shiga, Japan). Quantitative reverse-
transcriptase–PCR was performed in the Thermal Cycler Dice Real
Time System (Takara Bio) using SYBR Premix Ex Taq (Takara Bio).
Primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were used as an endogenous control for data normalization. Sequences
of the primers specific for ELOVL and CerS isozymes, STAT1, STAT3,
and GAPDH are shown in Supplementary Table S1 online.
siRNA transfection
The siRNAs for STAT1 and STAT3 were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). NHEKs were grown at 40–50% con-
fluence, and siRNA (5 nM) was transfected into the cells by incubating
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with the HiPerFect Transfection Reagent (Qiagen, Dusseldorf,
Germany) according to the manufacturer’s instructions. After transfec-
tion, cells were cultured for further 24 hours until stimulation.
Statistical analysis
All data were expressed as mean±SD. All experiments were repeated
for at least three times. For pair-wise comparisons, Student’s t-test was
used.
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